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Abstract
Glycation involves the non-enzymatic addition of reducing sugars and/or their reactive degradation products to amine
groups on proteins. This process is promoted by the presence of elevated blood glucose concentrations in diabetes and occurs with various proteins that include human serum albumin (HSA). This review examines work that has been conducted
in the study and analysis of glycated HSA. The general structure and properties of HSA are discussed, along with the reactions that can lead to modification of this protein during glycation. The use of glycated HSA as a short-to-intermediate
term marker for glycemic control in diabetes is examined, and approaches that have been utilized for measuring glycated
HSA are summarized. Structural studies of glycated HSA are reviewed, as acquired for both in vivo and in vitro glycated
HSA, along with data that have been obtained on the rate and thermodynamics of HSA glycation. In addition, this review
considers various studies that have investigated the effects of glycation on the binding of HSA with drugs, fatty acids and
other solutes and the potential clinical significance of these effects.
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1. Introduction

Two of the most prevalent forms of this disease are types 1
and 2 diabetes [1]. In type 1 diabetes, insufficient production of
insulin is caused by an autoimmune response in which the body’s
immune system attacks insulin-producing pancreatic beta cells
[1, 2]. Type 1 diabetes is also known as juvenile-onset, immunemediated or insulin-dependent diabetes. Patients with this type
of diabetes require daily insulin injections for survival. Type 1
diabetes accounts for approximately 5–10% of individuals who
have diabetes. Type 2 diabetes is also known as non-insulin dependent or adult-onset diabetes; this is the most common form
of diabetes and accounts for 90–95% of individuals with this
disease. Type 2 diabetes is caused by an inadequate cellular response to insulin (i.e., by muscle, liver, or adipose cells), or “insulin resistance”, and is strongly associated with factors that include obesity, age, and family history [1, 2].

Diabetes occurs in 366 million people worldwide and is projected to affect 552 million people by 2030 [1]. In the United States
alone, an estimated 25.8 million people have this disease [2]. Diabetes can be described as a group of disorders that result from
insulin deficiency and/or insulin resistance. Insulin is a hormone
produced in the pancreas and is responsible for the regulation of
glucose in the circulation [3]. The presence of either insulin deficiency or insulin resistance in diabetes produces an abnormal increase in blood glucose, resulting in a condition known as hyperglycemia. The high blood glucose concentrations seen in diabetes
can lead to a number of detrimental health effects, ranging from
an increased risk of heart disease and stroke to kidney disease,
blindness, and lower limb amputations [4–8].
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Figure 1. The process of glycation, which begins during early stage glycation (a) with the reaction of a reducing sugar such as d-glucose with a free
amine group on a protein to form a reversible Schiff base, followed by the formation of a more stable Amadori product (i.e., fructosyl–lysine, or
FL, in the case of glucose). The open chain glucose adducts can also convert to the closed forms that are shown above, which represent an N-substituted aldosylamine in the case of the Schiff base or an N-substituted 1-amino-1-deoxyketose in the case of the Amadori product [15]. These early
stage glycation reactions can later be followed by additional events during advanced stage glycation (b) that lead to the formation of advanced glycation end-products (AGEs). More details on the structures of FL and common AGEs are provided in Figure 6.

Many of the long-term effects of diabetes can be related to the
process of protein glycation. Glycation involves the non-enzymatic
addition of reducing sugars and/or their reactive degradation products to primary or secondary amine groups on proteins [9, 10]. Early
stage glycation involves the nucleophilic attack of a reducing sugar
with primary amine groups on proteins to form a Schiff base, as
shown in Figure 1(a). This intermediate product can then undergo
a slow rearrangement to create a more stable Amadori product, or
ketoamine (i.e., fructosyl–lysine, or FL, when this reaction involves
glucose) [11–15]. Further oxidation, dehydration, and cross-linking
steps can then occur, such as through the formation of reactive dicarbonyl compounds. These latter compounds exhibit significantly
enhanced reactivity for sites such as arginine and lysine residues on
proteins, as illustrated in Figure 1(b), with the result being the creation of advanced glycation end-products (AGEs) [12].
The study of proteins containing either early stage glycation
products or AGEs has become of great interest due to the suspected
effects of glycation on protein function and tissue damage during
diabetes. This effect has been well-studied for proteins with long life
spans, such as collagen and lens crystallin [16, 17], as well for some
proteins with shorter life spans, such as hemoglobin [18]. However,
there has also been an increasing interest in the glycation of human
serum albumin (HSA) and closely-related proteins (e.g., bovine serum albumin, or BSA). This interest is illustrated in Figure 2 by the
increasing number of publications that have appeared on this topic
over the last few decades, and especially over the last ten years.
This review will discuss past and recent reports that have ex-

amined the glycation of albumins, and especially HSA. This will
include a discussion of the structure and function of HSA, the process of glycation, and the measurement of glycated HSA for clinical purposes. The types of structural modifications that can appear as a result of glycation on albumin and the analysis of these
modifications will also be considered. The rate and thermodynamics of glycation for HSA will be examined. In addition, the binding of drugs and solutes to glycated HSA and the possible clinical
significance of glycation-related modifications on the function and
behavior of HSA will be discussed.
2. Structure and function of human serum albumin
HSA is the most abundant protein in human plasma or serum.
This protein is normally present in serum at concentrations ranging from 30 to 50 g/L and accounts for approximately 60% of the
total protein content in serum [19, 20]. HSA has a molecular weight
of 66.7 kDa and is composed of a single polypeptide chain with 585
amino acids and 17 disulfide chains. The crystal structure of HSA
reveals a globular heart-shaped protein composed of approximately
67% α-helices, 23% extended chains, and 10% β-turns (see Figure 3)
[19, 21–25]. The N-terminus and 59 lysine residues can act as potential sites for the formation of early stage glycation products on this
protein, as illustrated by the reaction in Figure 1, although not all of
these groups are equally susceptible to this reaction [19, 26]. HSA
also has 24 arginines that, along with the lysines and N-terminus,
could potentially be involved in the formation of AGEs [19].
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Figure 2. Number
of publications that
have appeared over
the last three decades
that are related to the
topic of glycation involving albumin or
human serum albumin (HSA). These
numbers were obtained on SciFinder
in February 2013 using the key terms
“glycated” or “glycosylated” and “albumin” or “HSA”.

Figure 3. The crystal structure of
HSA. The locations of the main drug
binding sites in this protein (i.e., Sudlow sites I and II) are shown, as well
as the locations for several lysines
that have often been reported to take
part in glycation. This structure was
generated using Protein Data Bank
(PDB) file ID: 1AO6.

HSA is involved in many physiological processes. For instance,
this protein aids in the regulation of osmotic pressure and pH in
blood. In addition, HSA mediates lipid metabolism, sequesters

toxins, and works as an antioxidant (i.e., it binds free radicals) [19].
Another important function of HSA is its action as a transport protein for a wide range of solutes that include some low mass hor-
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mones, fatty acids, and drugs [19, 24, 27–32]. There are several binding sites located in the structure of this protein. For example,
crystallographic studies have shown that HSA has various binding
sites for fatty acids [27, 30]. This protein also has two major binding
sites for drugs (i.e., Sudlow sites I and II, as shown in Figure 3), in
addition to several minor sites for small solutes [19, 24, 31–34]. Sudlow site I is located in sub-domain IIA of HSA and is also known as
the warfarin–azapropazone binding site. This region tends to bind
to bulky heterocyclic compounds, such as warfarin, azapropazone,
and phenylbutazone [19, 24, 31, 35]. Sudlow site II is located in subdomain IIIA of HSA and is also referred to as the indole–benzodiazepine binding site. This site is the primary binding region on
HSA for aromatic compounds such as ibuprofen and indole-containing compounds (e.g., l-tryptophan) [19, 24, 31, 36].
3. Measurement of glycated albumin
The measurement of glycated HSA (or “glycated albumin”,
GA, as it is often called in the clinical literature) has been of interest for a number of years as a complementary tool to standard assays using glucose or glycated hemoglobin (i.e., hemoglobin A1c,
or HbA1c) to monitor glycemic control in diabetic patients. Blood
glucose is a standard test for the diagnosis and monitoring of diabetes, but only provides information on the glycemic status of a
patient at a particular moment in time [37]. HbA1c is an accepted
biomarker for providing a long-term record of glycemic control
over a period of 2–3 months, as made possible by the life span of
approximately 90–120 days for hemoglobin in red blood cells [38,
39]. However, it has been suggested that HbA1c may not be suitable for evaluating patients with unstable blood glucose concentrations, and the accuracy of this marker can be affected by the
presence of hemoglobin variants [40], recent blood transfusions or
diseases such as hemolytic anemia and renal failure, which can affect the production and effective life span of red blood cells in the
circulation [41, 42].
These limitations in current methods have generated interest
in other markers and tests for the assessment of glucose control,
especially for examining the control of blood glucose over shortto-intermediate lengths of time [38]. The utilization of glycated
HSA for this purpose has been suggested because the half-life of
HSA in the blood is only 12–21 days [37–39]. This means that assays for glycated HSA, or related markers, can provide information on glucose control over a period of roughly of 2–3 weeks. This
feature, in turn, could help physicians to detect deteriorating control of blood glucose before any noticeable changes in HbA1c occur [37, 43, 44].
Fructosamine assays have been explored by clinical laboratories as means for measuring glycation that is mainly related to
HSA [37, 38, 45]. The term “fructosamine” (often abbreviated as
“FA”) typically refers to all ketoamine linkages that result from the
glycation of serum proteins. Because HSA is the most abundant of
the serum proteins, fructosamine is predominantly a measure of
glycated HSA, contributing ~ 90% to the total [41, 42]. As a result,
fructosamine assays tend to be used when glycemic control needs
to be examined over a period of 1–3 weeks [37, 38, 42]. Colorimetric methods such as the thiobarbituric acid (TBA), nitroblue tetrazolium (NBT) and hydrazine-based assays have been employed
to measure glycated serum proteins [45–47]. For example, the NBT
assay relies on the ability of N-substituted ketoamines to reduce
the dye nitroblue tetrazolium in a basic solution, generating a colored product [45, 48]. Although fructosamine assays are popular in
some countries, they have not seen as much use in the U.S., partly
due to difficulties encountered in the commercialization of such
methods [38]. Further details on the performance characteristics of
these techniques are provided in Refs. [38, 42–47].
The concentration of glycated HSA can be measured directly
by a number of techniques. These methods include boronate affinity chromatography [38, 49–55], immunoassay-related techniques
(e.g., enzyme-linked immunosorbent assays or radio-immunoassays) [38, 56, 57] and enzymatic methods [58–61]. Profiling of gly-

cated proteins in human serum, including HSA, has also been
explored using boronate affinity chromatography followed by tandem mass spectrometric detection [62]. The boronate affinity chromatographic methods make use of the interaction between sugar
residues and a binding agent such as phenylboronic acid; this process allows for the retention and separation of glycated HSA from
non-glycated HSA (see Figure 4), with the retained species later
being detected and quantified by an on-line or off-line method
(e.g., mass spectrometry or an immunoassay) [38, 49–53, 55]. Boronates have also been used in an enzyme-linked boronate immunoassay to measure glycated HSA [57]. One current clinical assay
based on an enzymatic method utilizes an albumin-specific proteinase (i.e., ketoamine oxidase) to digest glycated HSA, followed
by treatment with a fructosaminase to oxidize the glycated amino
acids and produce hydrogen peroxide, which is then measured
[59–61]. Raman spectroscopy [63], refractive index measurements
[64], capillary electrophoresis [65] and other electrophoretic methods [66, 67] have also been explored as alternative techniques for
measuring glycated albumin.
The clinical assays for glycated HSA typically express their results in terms of the ratio of the amount of glycated HSA versus
the total amount of HSA that is present. This feature means that
these methods are not generally affected by changes in the overall
concentration of HSA [38, 41]. Prior work from the 1980s estimated
that 6–13% of HSA was glycated in healthy individuals, with this
amount increasing by up to 20–30% in diabetic patients [26, 38, 68,
69, 70]. A recent review noted that a normal reference range of 11–
16% is used with a commercial enzymatic-based method, and current assays based on affinity chromatography often have lower reference values in the range of 0.6–3% [38]. However, all current
methods tend to give typical glycated HSA values for diabetic patients that are 2- to 5-fold higher than normal levels [38]. Altered
albumin metabolism can affect glycated HSA measurements in patients that suffer from proteinuria, hepatic cirrhosis or hypothyroidism [41]. In addition, elevated amounts of glycated HSA have
been noted to occur with several vascular complications and to be
linked to immune function, oxidative stress, cholesterol homeostasis, and atherosclerosis [39].
4. Structural analysis of glycated albumin
The process of glycation has been found to have possible effects on both the structure and function of HSA [26, 71]. For instance, several reports have found altered drug binding with this
protein as a result of glycation [71–75], as will be discussed in Section 6. The study of alterations in the structure of HSA following
glycation has involved the use of radio-labeling [76–78], colorimetric assays [48], fluorescence spectroscopy [26, 79–82], infrared
spectroscopy [79], circular dichroism [71, 82, 83], and NMR spectroscopy [84]. In addition, work based on immunoassays [79–85],
electrophoresis [81, 86] and HPLC [78, 81, 87–89] has provided information on the total glycation levels or on the amount of specific AGEs that are present within albumin. Some of these approaches again include the prior isolation of modified albumin
by methods such as boronate affinity chromatography [38, 49–55,
76, 78, 79, 90–92].
More detailed information on glycated-related modifications
has been obtained by using mass spectrometry. For instance, liquid chromatography–mass spectrometry (LC–MS) and liquid
chromatography–tandem mass spectrometry (LC–MS/MS) have
been used to locate and identify glycation sites in albumin [92–97],
to identify glycated peptides obtained from serum proteins [91],
and to look at the sites involved in the related process of galactation (i.e., the addition of galactose to an amine group) [98] and in
the formation of some AGEs [99, 100]. High resolution mass spectrometry (HRMS) [101] and tandem mass spectrometry (MS/MS)
[101, 102] have also been used to detect glycated peptides or to identify glycation sites. Fourier transform mass spectrometry (FTMS)
has been utilized to detect and identify glycated peptides from
HSA [103]. Gas chromatography–mass spectrometry (GC–MS)
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Figure 4. Use of a column and support containing a boronate ligand (e.g.,
phenylboronic acid) for the
retention of glycated HSA.
The active binding agent
in this process is the tetrahedral boronate anion,
which forms under alkaline conditions.

has been employed to investigate glycation at the N-terminus of
HSA [104]. In addition, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI–TOF MS) has been
used to estimate the overall extent of modification for glycated
HSA, to study glycated BSA, to locate sites for early stage glycation
products in HSA, to identify various AGEs in HSA, and to compare
the extent of modification at various regions of glycated HSA [80,
92, 102, 105–111].
The process of glycation can be divided into several stages [10–
12]. The first stage of this process, as shown earlier in Figure 1(a),
involves the combination of a reducing sugar such as glucose with
primary amine groups (e.g., lysine residues or the N-terminus of
a protein) to form a reversible Schiff base; this product can then
slowly rearrange to form an Amadori product [10–14]. Fructosyl–
lysine (FL, see Figure 1) is the major Amadori product produced in
vivo and has been found to occur at various locations in glycated
HSA. Table 1 summarizes the results of numerous studies that
have examined the glycation process and the creation of Amadori
products for both in vitro and in vivo glycated HSA [76, 78, 80, 93–
95, 97, 101, 105–108, 110].
The combined list of modification sites that have been reported
for FL and Amadori products includes all 59 lysines in HSA (see
Figure 5). However, only a relatively small number of these residues appear to account for most of the Amadori products and
modifications that are found in glycated HSA. As Figure 5 illustrates, lysine 525 has consistently been found to be a major site
for the formation of such products within both in vivo and in vitro
glycated HSA [76, 78, 108]. Other glycation sites that have been observed in at least half of the reported studies in Table 1 include lysines 439, 199, 51, 378, 545, 12, 233, 276, 281, 317 and 323. It is interesting to note that lysine 525 and many of these same lysines
have been reported to be important sites for the addition of galactose to HSA in vitro [98]. An additional 23 lysine residues have
been found to be modified for glycated HSA in at least four of the
reports listed in Table 1. Besides these lysine residues, the N-terminus has been noted in some reports to be a site for glycation in
HSA [80, 104, 106, 108]. Factors involved in determining the relative
susceptibility of these lysines and the N-terminus to glycation include local acid–base catalysis effects, the accessibility of the site

to the solvent or the environment, and the local pKa for the amine
group at each site [78, 96, 106, 108, 110].
The next stage of the glycation process involves the oxidation
of adducts on glycated proteins or free sugars to form intermediate
reactive dicarbonyl compounds, or α-oxaloaldehydes [28, 88, 112–
118]. The α-oxaloaldehydes that have been most commonly correlated with diabetes, kidney disease, and cardiovascular disease in
vivo are glyoxal, methylglyoxal, and 3-deoxyglycosone [89, 115]. The
concentrations of these α-oxaloaldehydes typically increase from
sub-nanomolar concentrations in normal individuals to micromolar concentrations in a number of diseases [116]. α-Oxaloaldehydes
can react with both lysines and arginines to form AGEs, as illustrated in Figure 1(b), and can also lead to the modification of cysteine residues [81]. AGE formation on plasma proteins is mediated
by a number of competing processes that include the oxidation of
sugars, lipids, or protein-bound sugar adducts and the counteracting removal of reactive dicarbonyl compounds by the glyoxylase
pathway or through natural protein degradation [116].
Table 1 includes a list of AGEs that have been observed in studies of both in vitro and in vivo glycated HSA [80, 96, 97, 105–108, 110].
Examples of these AGEs are shown in Figure 6. As indicated in
Table 1, methylglyoxal-derived hydroimidazolone isomer 1 (MGH1) and glyoxal-derived hydroimidazolone isomer 1 (G-H1) have
been seen in several studies for in vitro or in vivo glycated HSA.
The corresponding hydroimidazolone derived from 3-deoxyglucosone (3-DG-H1, isomer 1) has also been observed in these samples. Other possible AGEs that have been reported for both in vivo
and in vitro samples of glycated HSA include additional products
related to arginine, such as tetrahydropyrimidine (THP); products related to lysines, such as Nε-carboxyethyl–lysine (CEL), Nεcarboxymethyl–lysine (CML) and pyrraline (Pyr); and products
related to either lysines or arginines, such as 1-alkyl-2-formyl-3,4glycosyl-pyrrole (AFGP). In addition, the arginine-related products argpyrimidine (ArgP) and imidazolone B (IB) have been observed for glycated HSA in vitro [99, 100, 106, 107].
Some studies have compared the relative amounts of these
AGEs that can be found in HSA and the residues that may take
part in these modifications. For instance, minimally glycated
HSA that was prepared in vitro was found to contain mainly FL
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Table 1. Modification sites and adducts that have been reported for glycated human serum albumin (HSA).a
Modification
process [Ref.]

Sample (glycation conditions)b
and analysis methods

Modification sites identified

Major adducts

Glycation [76]

In vivo sample; tritium labeling, boronate
affinity chromatography, cation exchange
chromatography and amino acid analysis
In vivo sample; tritium labeling, boronate
affinity chromatography, HPLC and amino
acid analysis
In vitro sample (330-fold mol excess glucose
vs. 1.5 mM HSA, 37 °C, 28 days); LC–MS/MS

Major site: K525

FL/Amadori products

Major site: K525; other significant sites: K199, K233, K281,
K439; additional sites identified: K12, K317, K351, K534

FL/Amadori products

K12, K20, K41, K51, K73, K136, K137, K159, K162, K199, K205,
K233, K262, K276, K281, K313, K317, K323, K351, K378,
K389, K402, K432, K436, K439, K475, K500, K519, K525,
K541, K545, K557, K574
K525 > K233 > K136/K137 > K199, K64/K73, K439, K317,
K274/K276 > K534 > K389c
K524/K525 > K162 > K276 > K359 > K351 > K233; additional
sites identified: K12, K51, K64, K174, K181, K262, K378,
K414, K475, K541, K545d
K4, K41, K73, K137, K181, K190/K195, K199/K205, K225/
K233, K323,e K351, K378, K413/K414, K432, K436/K439,
K466, K519, K524/K525, K536, K545, K564/K573
Preferential sites: K525, K240, K233, K51, K136, K137, K73;
other sites: K41, K64, K93, K106, K159, K174, K181, K195,
R218, K262, K274, K323, K359, K372, K378, K389, K402,
K413, K432, K436, K439, K444, K466, R472, K475, K500,
K519, K573d
K51, K137, K162, K225, K233, K276, K313, K323, K351, K378,
K413, K444, K525, K536, K545, K573

FL/Amadori products

Potential sites: K41, K64, K93, K106, K317, K323, K359, K372,
K402, K439, K444, K525, K541, K545, K557, K560, K564,
K573, K574, R10, R98; Other potential sites: K4, K51, K281,
K286, K313, R160, R209
K12, K51, K159, K199, K205, K286, K378, K439, K525, K538;
R160, R222, R472

FL/Amadori products and
AGEs

Glycation [78]
Glycation [94]

Glycation [95]

In vivo sample; LC–MS

Glycation [93]

In vivo samples; boronate affinity
chromatography and LC–MS/MS

Glycation [101]

In vitro sample (370-fold mol excess glucose
vs. lyophilized HSA, 80 °C, 25 min);
13C-labeling, HPLC, HRMS and MS/MS
Plasma sample incubated with 30 mM glucose
(37 °C, 24 h); 12C/13C-labeling, boronate
affinity chromatography, LC–MS/MS

Glycation [97]

Glycation and AGE
formation [96]
Glycation and AGE
formation [80]

In vitro sample (330-fold mol excess glucose
vs. 1.5 mM HSA, 37 °C, 28 days); LC–MS/MS,
MALDI–TOF MS
In vitro sample (3125-fold mol excess glucose
vs. 16 μM HSA, 40 °C, up to 115 days);
MALDI–TOF MS

Glycation and AGE
formation [107]

In vitro sample (commercial preparation
of minimally-glycated HSA); peptide
fractionation, MALDI–TOF MS

Glycation and AGE
formation [106]

In vitro samples (24- to 48-fold mol excess
glucose vs. 0.63 mM HSA, 37 °C, 2–5 weeks);
peptide fractionation, MALDI–TOF MS

Glycation and AGE
formation [105]

In vitro sample (commercial preparation of
minimally-glycated HSA); 16O/18O-labeling,
peptide fractionation, MALDI–TOF MS
In vitro samples (24-fold mol excess glucose vs.
0.63 mM HSA, 37 °C, 2–5 weeks); 16O/18Olabeling, peptide fractionation, MALDI–TOF
MS

Glycation and AGE
formation [108]

Significant sites: K525/K524/R521 > N-Terminus, K93/R98,
K276/K286, K414/K439 > R197 > K199, K281, R428; Other
sites: K4, K12, K174, K190, K205, K212, K262, K313, K317,
K413, K545, K557, K560, K564, K573, K574; R10, R186,
R209, R410
K159, K212, K323, K413, K432, K439, K525; R81, R114, R218
Regions with highest levels of modification (likely sites): 1–10
(N-terminus*/K4/R10) or 42–51 (K51), 521–531 (K525*/
K524), 275–286 (K281*/K276/K286), 21–41 (K41), 82–93
(K93), 87–100 (K93/R98), 101–119 (K106/R114/R117), 146–
160 (K159/R160), 360–372 (K372); other regions: 426–442
(K439*/R428), 61–82 (K64/K73/R81), 142–153 (R144/
R145), 154–167 (K159), 189–208 (K199), 209–227 (K212/
R218), 241–257 (R257), 324–336 (R336), 373–389 (K378/
K389), 414–428 (K414/R428), 502–518 (K519) f
K12, K162, K174, K190, K199, K205, K276, K281, K286, K313,
K317, K372, K432, K525, K545, K557, K560, K564, K573/
K574; R10, R98, R160, R197, R209, R428, R484, R485

Glycation and AGE
formation [110]

In vivo sample; 16O/18O-labeling, peptide
fractionation, MALDI–TOF MS

AGE formation with
methylglyoxal [99,
100]
Galactation [98]

In vitro samples (5-fold mol excess of glucose
vs. 0.1 mM HSA at 37 °C, 24 h); LC–MS/MS

R410 > R114, R186, R218, R428

In vitro samples (8- to 1500-fold mol excess
galactose vs. 1.2 μM HSA, 37–56 °C, 0.01–
8 days); boronate affinity chromatography,
LC–MS/MS

K12, K233, K276/K281, K414, K525

FL/Amadori products
FL/Amadori products
FL/Amadori products
FL/Amadori productsand
AGEs

FL/Amadori products and
AGEs

FL/Amadori products and
AGEs (e.g., AFGP, ArgP,
CEL, CML, 3DH-H1,
G-H1, Pyr, THP)
FL/Amadori products and
AGEs (e.g., AFGP, ArgP,
CEL, CML, 3-DG-H1,
G-H1, IB, MG-H1, Pyr,
THP)
FL/Amadori products and
AGEs (e.g., AFGP, CEL,
CML, Pyr)
FL/Amadori products and
AGEs (e.g., AFGP, CEL,
3-DG-H1, G-H1, Pyr,
MG-H1)

FL/Amadori products and
AGEs (e.g., AFGP, CEL,
CML, 3-DG-H1, G-H1,
MG-H1, Pyr, THP)
MG-H1, ArgP, CEL,
methylglyoxal-derived
lysine dimer
Galactosyl–lysine

a. A ranking of the modified residues is provided if such information appeared in the given references. If no ranking was provided, then the modification sites are listed
in their order of appearance in HSA. List of abbreviations: AFGP, 1-alkyl-2-formyl-3,4-glycosyl-pyrrole; AGE, advanced glycation end-product; ArgP, argpyrimidine;
CEL, Nε-carboxyethyl–lysine; CML, Nε-carboxmethyl–lysine; 3-DG-H1, 3-deoxyglucosone-derived hydroimidazolone, isomer 1; FL, fructosyl–lysine; G-H1, glyoxalderived hydroimidazolone, isomer 1; IB, imidazolone B; MG-H1, methylglyoxal-derived hydroimidazolone, isomer 1; Pyr, pyrraline; THP, tetrahydropyrimidine.
b. A typical ratio of glucose to HSA that is found in blood during diabetes is 24:1 (mol/mol) and the normal concentration of HSA in serum is generally 0.53–0.75 mM
(i.e., 35–50 g/L).
c. The order of these results are those for the “Diabetic patient” in Table 1 of Reference [95]. A similar order was obtained for other samples that were examined.
d. The values differ from the published residues by 24 amino acids to exclude the signaling peptide that was included in the sequence in this study and to make the listed
sequence assignments consistent with the rest of the table.
e. This paper included an entry for K322 which should have instead been K323, according to a personal communication with the authors.
f. This study focused on quantitative studies based on the examination of a decrease in the abundance of non-modified peptides from the indicated regions. The
suspected modification sites leading to each decrease are those contained in the given regions, as based on the sequence of HSA, identified modifications, and prior
studies of glycated HSA; in cases where a particular residue is a well-known modification site from prior work, this residue is indicated by an asterisk. This list
combines the modified regions that were seen for two in vitro samples that were incubated either two or five weeks with the stated amount of glucose. For 502–518,
which contains no lysine or arginine, K519 is given as a possible site of modification because it is immediately next to the enzymatic digestion site for this peptide.
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Figure 5. Number of reports from the literature (see Table 1) that have identified glycation-related modifications at the various lysine or arginine
residues in HSA. The three regions of the bar graphs show the number of reports that have involved in vitro samples (bottom section, dark gray;
up to 8 total papers), in vivo samples (middle section, light gray; up to 5 total papers) or plasma that was spiked with glucose and incubated under
in vitro conditions (top section, intermediate gray; up to 1 paper).

and CML plus minor amounts of others AGEs (e.g., ArgP, 3DGH1, G-H1, MG-H1, THP and some 3-deoxyglucosone-derived lysine dimer); in vitro highly glycated HSA that was examined by the
same methods contained the same AGEs plus pyrraline and high
amounts of FL [88, 89]. Quantitative screening for several types of
AGEs in plasma proteins, including HSA, indicated that hydroimidazolones were a major type of modification that occurred in
this group. Of these, MG-H1 was estimated to be present in about
2% of HSA from normal healthy individuals, followed by 1% for
3DG-H (e.g., 3DG-H1) and 0.1% for G-H1 [117]. AGEs such as CML,
CEL were found in the same types of samples at amounts just below those of G-H1, while only small amounts of cross-linked species like pentosidine and methylglyoxal-derived lysine dimer were
detected. The levels of these modifications were found, in general,
to increase in patients with renal failure [117].
It has been noted that the reaction of methylglyoxal with
0.11 mM HSA at pH 7.4 and 37 °C tends to be selective for arginine
residues at a methylglyoxal concentration of 1 mM, with a much
higher methyglyoxal concentration (100 mM) leading to increased
modification for arginines as well as the modification of some lysines [81]. Of the 24 arginines that are present in HSA, 21 of these
have already been proposed to take part in some type of AGE formation, as is illustrated in Figure 5. This observation agrees qualitatively with in vitro studies of HSA from Ref. [81], in which the
incubation of this protein with over a 900-fold mol excess of
methylglyoxal resulted in the modification of an average of 19 out
of 24 arginines per HSA. The arginines which have been found
to be modified in four or more studies of AGEs for in vitro or in
vivo glycated HSA are R128, R428, R10, R98, R114, and R160;
another four arginines have been noted to be modified in at least
three studies of glycated HSA. Studies that have examined the in
vitro reaction of methylglyoxal with HSA have found that R410 is a
particularly active site for this pair of reactants, followed by R114,
R186, R218 and R428 [99, 100].
The use of glycated HSA as a biomarker for glycemic control, as
discussed in Section 3, is based on the fact that the extent of glycation for this protein will depend on the time allowed for glycation
and the amount of glucose that is available for reaction with HSA.
As will be shown in Section 5, the types of modifications that occur

on glycated HSA will also depend on these factors. Furthermore,
this means some variations in glycation-related modifications may
occur between samples of in vitro glycated HSA that are prepared
under different conditions [106, 108], between in vivo glycated HSA
and in vitro glycated HSA that is prepared under non-physiological conditions [119], or even between in vivo samples that are acquired from different patients [93, 111]. Despite this variability,
there are strong similarities between the results of structural studies that have been obtained for in vivo and in vitro glycated HSA.
For instance, lysine 525 has consistently been found to be a major
glycation site in both types of samples [76, 78, 108]. In addition, all
lysines that have been found to be modified in five or more studies
of glycated HSA have been detected both in vivo and in vitro (see
Figure 5); glycation at many of the remaining lysines in HSA has
been observed in these two types of samples as well. There is also
good agreement between the types of AGEs that have been found
for in vivo and in vitro glycated HSA (see Table 1) and in the arginines that have been most often observed to take part in glycationrelated modifications in these samples (see Figure 5).
Several recent studies have further noted close similarities between in vivo results and those for in vitro glycated HSA that has
been prepared using glucose/HSA concentrations and incubation
conditions that mimic those found in serum during diabetes. These
similarities include the specific residues that are being modified [76,
78, 105–108, 110], the types of modifications that occur [105–107, 110],
the relative order of modified lysines versus lysine 525 in terms of
their formation of fructosyl–lysine [93, 108], and the observed modification patterns versus in vivo glycated HSA that has a similar extent of overall glycation [106, 108, 110]. Together, these data indicate
that in vitro glycated HSA can be a useful model for in vivo glycated
HSA in many situations, especially if the two types of samples have
been created or generated under similar reaction conditions.
5. Kinetic and thermodynamic studies of albumin
glycation
The rate of modification and thermodynamics of the glycation process for HSA have been examined in a few studies. For instance, early work in this area confirmed the reaction model that
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Figure 6. Structures of fructosyl–lysine (FL) and examples of advanced glycation end-products (AGEs) that have been reported for glycated HSA
(see summary in Table 1).

is shown in Figure 1(a) for the early stage glycation of HSA [15].
This process involves biphasic kinetics, in which the reversible
combination of glucose with a free amine group to create a Schiff
base quickly reaches an equilibrium (i.e., in a matter of hours under the conditions used in Ref. [15]), followed by a much slower
conversion of the Schiff base to an Amadori product. The average
rate constants for the initial association or dissociation of glucose
with amine groups on HSA were determined to be 1.5 M− 1 h− 1 (or

4.2 × 10− 4 M− 1 s− 1) and 0.39 h− 1 (or 1.1 × 10− 4 s− 1), respectively
(Note: unless otherwise indicated, the rate constants and equilibrium constants listed in this review were obtained at pH 7.4 and
37 °C). The average association equilibrium constant for this process was 3.9 (± 0.3) M− 1. The rate constant for the formation of
Amadori products was estimated to be 0.026 h− 1 (7.2 × 10− 6 s− 1),
with these products being found to be quite stable and having a
half-life of at least 3 weeks [15].
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The net rate of glycation and modification for HSA has been investigated in a number of studies under in vitro conditions. The results of one such study are shown in Figure 7(a), as based on the
measurement of fructosamine and the overall degree of glycation
[106]. Similar trends have been noted when using the change in
mass that is observed over time for in vitro glycated HSA [111]. The
results in both Figure 7(a) and (b) were carried out under incubation conditions and using concentrations of glucose and HSA that
are representative of physiological conditions. The data show that
most modifications occur within the first three weeks of incubation,
followed by a more gradual change over longer incubation times
[106, 111]. Comparable trends have been noted in other reports examining the reaction of HSA or BSA with glucose or similar reagents
[77, 80, 120–122]. Besides incubation time, the effects of glucose concentration and pH on glycation have also been considered [122].
The formation over time of early stage glycation products versus AGEs has been investigated as well. As an example, both semiquantitative and quantitative studies of in vitro glycated HSA that
was prepared under physiological or diabetic-type conditions (i.e.,
a 24- to 48-fold mol excess of glucose versus 0.63 mM HSA) have
found that early stage glycation products such as FL dominate after incubation times of two weeks, with AGEs becoming more apparent after longer reaction times of up to five weeks [106, 108]. A
similar trend has been noted in vitro when using a larger excess of
glucose versus HSA during glycation (i.e., 3125-fold mol excess of
glucose versus 16 μM HSA) [80].
In some cases, the rate of formation of glycation products at
specific regions of HSA has been determined, as shown in Figure 7(b). It has been found through this research that different regions of this protein do vary in their rates of glycation product formation [108]. For instance, the pseudo-first order rate constants for
the formation of glycation products at regions containing the Nterminus, K525, K439/R428 and K199 (or K205) have been estimated to be 2.5 × 10− 5, 2.2 × 10− 5, 1.1 × 10− 5 and 1.1 × 10− 5 min− 1,
respectively, over the first two weeks of incubation, with values
of 1.3 × 10− 5 min− 1 to 0.6 × 10− 5 min− 1 being obtained over five
weeks of incubation. Similar modifications at other regions of glycated HSA have been found to have pseudo-first order rate constants in the range of 10− 6 to 10− 5 min− 1 [108].
6. Binding of glycated albumin to drugs, fatty acids and
other solutes
Because glycation can modify the structure of HSA, there has
been interest in how these changes may affect the ability of HSA
to act as a binding agent for drugs and other solutes [70–75, 82, 110,
119, 123–131]. This topic has been of particular interest in recent
years as experiments examining the structure of glycated HSA
have found that modifications in this protein can occur on several
residues that are at or near Sudlow sites I and II, as illustrated in
Figure 3 [99, 100, 105–108]. Various methods have been employed
to examine the binding of solutes with glycated HSA to see if
any changes occur versus the interactions that are seen for normal HSA. These techniques have included fluorescence spectroscopy [71, 82, 83, 119], circular dichroism [83], ultrafiltration [119, 123,
130], equilibrium dialysis or rate of dialysis [70, 82, 124, 131, 132], and
chromatographic techniques such as the Hummel–Dreyer method
[130] or various forms of high performance affinity chromatography [72–75, 126–129].
Several reports have studied the effects that glycation may have
on drug and solute binding at the major binding regions for these
agents on HSA. For instance, warfarin and its enantiomers have
been used as site-selective probes for Sudlow site I of HSA [71–75,
83, 110, 126, 128, 133]. The changes that have been observed for binding by warfarin to HSA have been found to vary with the binding
conditions and the extent of glycation for HSA. For instance, early
reports using fluorescence spectroscopy or equilibrium dialysis at
20–25 °C noted a 6.9-fold decrease or 1.8-fold increase in the affinity for warfarin with in vitro glycated HSA that had high amounts
of glycation (i.e., as prepared using up to a 165- to 3300-fold mol
excess of glucose versus HSA) [70, 71, 74]. An affinity decrease
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Figure 7. Change in (a) the total amount of glycation or (b) the
amount of modification at specific residues as a function of time for in
vitro glycated HSA. The data in both plots were acquired at pH 7.4 and
37° C for 0.63 mM HSA incubated with 15 mM glucose. In (b) the relative extent of modification is given by the value of the measured glycated/control index, as obtained for residues 1–10 (○), 521–531 (□),
189–208 (Δ), and 426–442 (◊) and containing potential modification sites such as the N-terminus, R521/K525, K199/K205 and R428/
K439. Adapted with permission from Refs. [106, 108].

of ~ 20% for warfarin was observed using a pooled sample of in
vivo glycated HSA isolated from diabetic patients; in the same
study, a decrease in affinity of 30–60% was seen for in vitro glycated HSA that had been prepared by incubating a pooled sample
of normal HSA with a 67- to 270-fold mol excess of glucose [119].
Other experiments have examined the binding of warfarin with in
vitro glycated HSA that had been prepared by using glycation levels similar to those present in patients with diabetes, with no significant change in the overall binding or interactions at Sudlow
site I being observed when compared to normal HSA [74]. Little or
no change in binding was also observed for warfarin at pH 7.0 and
room temperature with in vitro glycated HSA that had moderate
amounts of modification [83], and when using chromatographicbased zonal elution studies to examine the overall binding of warfarin with entrapped samples of normal HSA or in vitro glycated
HSA with modification levels comparable to those seen in diabetic
patients [126]. One practical consequence of these latter observations is that no appreciable effect of glycation would be expected
in clinical and pharmaceutical studies that use warfarin as a siteselective probe with HSA that has levels of modification similar to
those seen in diabetes [74, 126].
Similar experiments have examined the binding of l-tryptophan as a site-selective probe for Sudlow site II of glycated HSA
and normal HSA [72–75, 110, 126, 128, 134]. Early studies using HSA
that was glycated in vitro in the presence of bound palmitic acid
did not show any apparent change in the affinity of l-tryptophan
versus normal HSA at 25 °C [132]. However, a later study found a
decrease in binding at 4 °C and when using a low amount of in
vitro glycation (i.e., 9-fold mol excess of glucose versus 0.6 mM
HSA), while an increase in binding was seen at a higher glycation
level (i.e., a 46-fold mol excess of glucose versus 0.6 mM HSA)
[82]. This result is consistent with recent competition experiments
carried out at 37 °C and using in vitro glycated HSA that contained
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an extent of modification similar to those found in diabetes; in this
latter work, a 4.7- to 5.8-fold increase in the association equilibrium constant for l-tryptophan at Sudlow site II was measured for
glycated HSA [74]. A similar, large increase in affinity was seen at
37 °C with comparable HSA samples but using a high-throughput
chromatographic method to examine the overall binding of l-tryptophan with normal HSA and in vitro glycated HSA [126]. Thus, in
the case of l-tryptophan, glycation would be expected to have an
effect in clinical and pharmaceutical research that uses this solute
as a site-selective probe with HSA [74, 126].
Another group of drugs that may have their binding to HSA affected by glycation are sulfonylureas [72, 73, 75, 110, 126–129]. Sulfonylureas are a form of oral medication that is used in the treatment of type 2 diabetes. These drugs are highly bound to HSA and
have been found to have multi-site interactions at both Sudlow sites
I and II [72, 73, 75, 110, 127, 128, 135]. Table 2 summarizes the results
of studies have examined the binding of several sulfonylureas with
glycated HSA that has been prepared in vitro and with various degrees of glycation similar to those found in diabetic patients [72, 73,
75, 128]. As this table indicates, the amount of HSA glycation has
been found to affect the affinity of this protein for these sulfonylurea
drugs. The size of this effect can vary from one drug to the next in
the same class or between different binding sites for the same drug,
and can lead to either an increase or decrease in affinity at a given
site. For instance, the changes in affinity seen at Sudlow sites I and
II in Table 2 range from 0.6-fold to 6.0-fold versus normal HSA for
the given set of sulfonylurea drugs. Similar effects and variations in
affinity at comparable levels of glycation have been noted in recent
studies examining the binding by many of the same sulfonylurea
drugs with in vivo samples of glycated HSA [110].
As Table 2 indicates, there is growing evidence that the amount
of glycation-related modifications can have a large effect on the
binding of a drug or solute with glycated HSA. This has been noted
not only for sulfonylurea drugs [72, 73, 75, 110, 128] but is also suggested by the apparent changes in affinity with glycation conditions that have been noted in the binding studies that were discussed earlier for warfarin [70, 71, 74, 119, 126] and l-tryptophan [74,
82, 126, 132]. In some cases, such as for warfarin, a large change
in the extent of glycation may be needed to see a change in binding, while for other solutes (e.g., l-tryptophan) these changes may
begin at small or moderate amounts of modification. It has been
further proposed through structural studies (see Section 4) that
the variations in binding that have been noted at particular sites
on HSA (e.g., Sudlow sites I and II) are probably related to that
changes in the amount and types of modifications that occur in
HSA with different degrees of glycation [72–75, 82, 83, 106, 108, 110].
The binding of other solutes with glycated HSA has also been
examined [26, 70, 83, 119, 122–25, 130, 131]. For instance, it has been
reported that the dye Bromocresol Purple has a decrease in binding with glycated HSA, especially when this protein is reacted with
glyceraldehyde, and that this change in binding is linked to the degree of modification [70]. A decrease in the binding capacity of salicylate has been observed for in vitro glycated HSA [122]. It was
found for in vitro glycated HSA with moderate amounts of glycation that there is a decrease in the binding of dansylproline, which
binds to Sudlow site II, but no measurable change for dansylamide, which binds to Sudlow site I; decreased binding was further seen for phenybutazone, ibuprofen and flufenamic acid [83].
The binding of in vivo glycated HSA with hemin did not change,
but a 50% decrease in affinity for bilirubin was observed [26]. A decrease in affinity of 30–50% was seen for ketoprofen in its binding
to a pooled sample of in vivo glycated HSA from diabetic patients,
while either no change or up to a 50% decrease was observed for in
vitro glycated HSA that had been prepared by using a 67- to 270fold mol excess of glucose [119]. In some studies, no change was
found in the free fraction of phenytoin in spiked serum samples
obtained from diabetic patients or normal individuals [123, 124],
while another report found a significant decrease in the binding of
phenytoin and valproate in such samples but no change for digitoxin [131]. Other studies have observed slightly decreased binding
by diazepam to serum proteins in such samples [124, 125].

Table 2. Changes in the binding of various sulfonylurea drugs at
Sudlow sites I and II when comparing in vitro glycated HSA with
normal HSA.
Relative change in association equilibrium constant (↑ or ↓)a
Drug and binding site

gHSA1

gHSA2

gHSA3

Sudlow site I
Acetohexamide
Tolbutamide
Gliclazide
Glibenclamidec

↑ 1.4-fold
↑ 1.3-fold
N.S. (< 10%)
N.S. (< 5%)

N.S. (↓ 10%)b
↑ 1.2-fold
↑ 1.9-fold
↑ 1.7-fold

N.S. (< 5%)
↑ 1.2-fold
N.S. (↑ 11%)b
↑ 1.9-fold

Sudlow site II
Acetohexamide
Tolbutamide
Gliclazide
Glibenclamidec

↓ 0.6-fold
↑ 1.1-fold
↓ 0.8-fold
↑ 4.3-fold

↓ 0.8-fold
↑ 1.4-fold
↑ 1.3-fold
↑ 6.0-fold

N.S. (< 10%)
↑ 1.2-fold
↓ 0.6-fold
↑ 4.6-fold

a. This table is based on data obtained from Refs. [72, 73, 75, 128].
The results for each drug were obtained using the same preparations of in vitro glycated HSA and were measured at 37°C and
in the presence of pH 7.4, 0.067 M potassium phosphate buffer. The levels of glycation for the protein samples were as follows: gHSA1, 1.31 (± 0.05); gHSA2, 2.34 (± 0.13); and gHSA3,
3.35 (± 0.14) mol hexose/mol HSA. The relative changes listed
are all versus the following association equilibrium constants
that have been measured for normal HSA: Sudlow site I — acetohexamide = 4.2 × 104 M− 1, tolbutamide = 5.5 × 104 M− 1, gliclazide = 1.9 × 104 M− 1, glibenclamide = 2.4 × 104 M− 1; Sudlow site II
— acetohexamide = 13.0 × 104 M− 1, tolbutamide = 5.3 × 104 M− 1, gliclazide = 6.0 × 104 M− 1, glibenclamide = 3.9 × 104 M− 1. The term
“N.S.” stands for “not significant” and indicates an association equilibrium constant that was not significantly different from that for
normal HSA at the 95% confidence level.
b. The association equilibrium constant for this drug and sample of
glycated HSA was significantly different at the 90% confidence level
from the reference value for the same drug with normal HSA but was
not significantly different at the 95% confidence level.
c. Glibenclamide also binds to the digitoxin site of HSA, which may
have displayed a slight decrease in binding in going from normal
HSA to the samples of in vitro glycated HSA that are represented in
this table [128].

In addition to elevated amounts of protein glycation, diabetic
patients have been found to have higher concentrations of fatty acids in serum when compared to healthy individuals [136–138]. As
an example, in one early study it was proposed that an increase in
free fatty acid concentrations was correlated with an increase in
the free fraction of valproic acid in spiked serum samples from diabetic patients versus normal individuals [123]. In another study,
a 20-fold decrease in binding strength was reported for the fatty
acid cis-parinaric acid when comparing in vivo and in vitro glycated HSA with normal HSA [26]. Fatty acids can have many binding regions on HSA and often interact strongly with these sites [27,
30, 139–143]. In addition, some fatty acids can have direct competition with drugs on HSA or lead to allosteric effects during the
binding of drugs and other solutes with this protein [140, 141]. One
recent study examined the combined effect of glycation and several long chain fatty acids on the overall binding of HSA to a number of sulfonylurea drugs [144]. The results showed an increase in
the global affinity of glycated HSA for the drugs that were examined, and a similar decrease in affinity to both normal HSA and
glycated HSA for these drugs in the presence of many common
long chain fatty acids [144].
A question that has often been raised in the investigation of
drug and solute binding to glycated HSA is the possible clinical relevance of these interactions. The answer will depend on the drug
or solute that is being considered, the typical therapeutic or physiological range of the drug/solute, the regions on HSA that are involved in the interaction, and the degree of glycation for HSA. In
some cases, this effect can be minimal, as has been observed for
phenytoin or diazepam in spiked serum [123, 124] and warfarin in
the presence of in vitro glycated HSA that has amounts of modifi-
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cation similar to those seen in diabetes [73, 83, 126]. For other solutes and drugs, there may be a large change in affinity or binding, as has been observed in serum, for in vivo glycated HSA, or
for in vitro glycated HSA with glycation levels similar to those seen
in diabetes. Examples of this latter case include l-tryptophan [74,
126], cis-parinaric acid [26], bilirubin [26], and ketoprofen [119]. Although further data is needed on these effects for a broader range
of drugs, the results that have already been obtained suggest that
Sudlow site II may be more prone to Sudlow site I to such changes.
This generalization is illustrated by studies that have compared
the binding of glycated HSA to drugs and probes that are known to
bind to these two sites [72–75, 83, 110, 126, 127].
Even drugs with moderate changes in affinity might be affected
to a significant degree if they have a relatively narrow therapeutic range and/or undesirable effects at concentrations flanking this
range. For instance, the sulfonylurea results in Table 2 for in vitro
glycated HSA and similar data for in vivo glycated HSA [110] predict
that the free, biologically-active fractions of these drugs could differ
by 0.6- to 1.7-fold from what would be expected in serum at typical
therapeutic concentrations and in the presence of only normal HSA.
This difference is of concern for these drugs because a lower-thanexpected free fraction would lead to improper control of blood glucose, while a higher-than-expected free fraction might lead to hypoglycemia [72, 75, 128, 129, 135, 145]. In addition to these direct changes
in the free drug fractions, another way glycation may affect the behavior of such solutes is through the changes in drug–drug interactions that might occur as the affinities of one or both drugs are altered at Sudlow sites I and II or other regions of HSA [74, 128].

as a biomarker for diabetes control. Such data would also be expected to create a better understanding of how diabetes and glycation can alter the structure and function of proteins like HSA.
This improved understanding could, in turn, result in new tools
for studying the biochemical effects of diabetes and in the development of better treatment regimes for diabetic patients.

7. Conclusions
The glycation of HSA has been a topic of interest for several
decades and especially over the last ten years. Part of this interest is related to the clinical use of glycated HSA as a biomarker for
the control of blood glucose over short-to-intermediate periods of
time. To meet this need, a number of methods are now available to
clinical laboratories for either the direct or indirect measurement
of glycated HSA. With such methods, glycated HSA can be used as
a complementary biomarker to blood glucose and Hb1Ac for monitoring glycemic control in diabetic patients.
There has also been increasing interest in the effects glycation
may have on the structure of HSA. A variety of methods have been
employed for examining the number, location and types of modifications that can occur in glycated HSA. Many possible modification sites have been detected on this protein for both early stage
glycation products and AGEs, but a smaller subset of these sites
appear to take part in most of these reactions. Some information
on the similarities, or differences, between in vivo and in vitro glycated HSA has been acquired through such work. The overall rate
of glycation, the thermodynamics of this process, and the rate of
modification at specific regions have been considered in such studies. The role of glycation conditions on the types of modifications
that are formed has also been examined.
Related work has appeared on the possible effects glycation
may have on the properties of HSA, such as its ability to bind to
drugs and other small solutes. This research has again employed
various methods and has examined a growing list of solutes. This
work has included compounds that are known to bind to HSA at
specific regions (e.g., Sudlow sites I and II) and solutes with more
complex binding, such as drugs that have multi-site binding to
HSA (e.g., sulfonylurea drugs and fatty acids). The results have
shown that the effects of glycation on binding by HSA can vary
from one solute to the next, even within the same group of compounds, and can vary for the same solute at different sites on HSA.
These effects can be clinically significant and appear to vary with
the extent of glycation and the glycation conditions.
Given the importance of HSA and the relatively complex nature of glycation, it is anticipated that more research will be conducted in the future to obtain further information on this process
and on how it affects HSA. This information could lead to the development of more effective assays for measuring glycated HSA

et al. in

Clinica Chimica Acta 425 (2013)

74

Acknowledgments — This work was supported, in part, by
theNational Institutes of Health under grants R01 DK069629
and R01 GM044931.
References
[1] International Diabetes Federation diabetes atlas. 5th ed. Brussels,
Belgium: International Diabetes Federation; 2011.
[2] National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2011. Atlanta, GA: U.S.
Centers for Disease Control; 2011.
[3] Nelson DL, CoxMM, editors. Lehninger principles of biochemistry.
New York:W. H. Freeman and Company; 2005.
[4] Hartog JWL, Voors AA, Bakker SJL, Smit AJ, Veldhuisen DJV.
Advanced glycation end-products (AGEs) and heart failure:
pathophysiology and clinical implications. Eur J Heart Fail
2007;9:1146–55.
[5] Olijhoeka JK, Graafb YVD, Bangaa JD, Algrab A, Rabelinka TJ,
Visserena FLJ. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease,
stroke, peripheral arterial disease or abdominal aortic aneurysm.
Eur Heart J 2004;25:342–8.
[6] Perneger TV, Brancati FL,Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med
1994;121:912–8.
[7] Turk Z, Misur I, Turk N. Temporal association between lens protein glycation and cataract development in diabetic rats. Acta Diabetol 1997;34:49–54.
[8] Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lowerextremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care 1989;12:24–31.
[9] Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal,
methylglyoxal and 3-deoxyglucosone in the glycation of proteins
by glucose. Biochem J 1999;344: 109–16.
[10] Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Acad Sci
1912;154:66–8.
[11] NurstenH. TheMaillard reaction. Cambridge, UK: Royal Society of
Chemistry; 2005 .
[12] Lapolla A, Fedele D, Reitano R, et al. Mass spectrometric study of
in vivo production of advanced glycation end-products/peptides. J
Mass Spectrom 2005;40:969–72.
[13] Lapolla A, Fedele D, Seraglia R, Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update. Mass Spectrom Rev 2006;25:775–97.
[14] Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. A perspective on the Maillard reaction and the analysis of protein glycation
by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res 2009;8:754–69.
[15] Baynes JW, Thorpe SR, Murtiashaw MH. Nonenzymatic glucosylation of lysine residues in albumin. Methods Enzymol
1984;106:88–98.
[16] Perejda A, Uitto J. Nonenzymatic glycosylation of collagen and
other proteins: relationship to development of diabetic complications. Coll Relat Res 1982;2: 81–8.
[17] Rogozinski S, Blumenfeld O, Seifter S. The nonenzymatic glycosylation of collagen. Arch Biochem Biophys 1983;221:428–37.
[18] Jones RL, Cerami A. Nonenzymatic glycosylation of proteins in
diabetes mellitus. Recent Adv Diabetes 1984;1:173–80.
[19] Peters Jr T. All about albumin: biochemistry, genetics, and medical applications. San Diego: Academic Press; 1996.
[20] Tietz NW, editor. Textbook of clinical chemistry. Saunders: Philadelphia; 1986.

Review: Glycation

of human serum albumin

[21] Colmenarejo G. In silico prediction of drug-binding strengths to
human serum albumin. Med Res Rev 2003;23:275–301.
[22] Dockal M, Carter DC, Ruker F. The three recombinant domains of
human serum albumin. J Biol Chem 1999;274:29303–10.
[23] He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992;358:209–15.
[24] Otagiri M. A molecular functional study on the interactions
of drugs with plasma proteins. Drug Metab Pharmacokinet
2005;20:309–23.
[25] Choi EJ, Foster MD. The role of specific binding in human serum albumin adsorption to self-assembled monolayers. Langmuir
2002;18:557–61.
[26] Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of
human serum albumin alters its conformation and function. J Biol
Chem 1984;259:3812–7.
[27] Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol
1998;5:827–35.
[28] Koyama H, Sugioka N, Uno A, Mori S, Nakajima K. Effects of glycosylation of hypoglycemic drug binding to serum albumin. Biopharm Drug Dispos 1997;18:791–801.
[29] Ascoli GA, Domenici E, Bertucci C. Drug binding to human serum albumin: abridged review of results obtained with high-performance liquid chromatography and circular dichroism. Chirality
2006;18:667–79.
[30] Simard JR, Zunszain PA, Ha CE, et al. Locating high-affinity fatty
acid-binding sites on albumin by X-ray crystallography and NMR
spectroscopy. Proc Natl Acad Sci U S A 2005;102:17958–63.
[31] Sudlow G, Birkett DJ, Wade DN. Characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975;11:824–32.
[32] Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol
1976;12:1052–61.
[33] Sengupta A, Hage DS. Characterization of the binding of digitoxin
and acetyldigitoxin to human serum albumin by high-performance
affinity chromatography. J Chromatogr B 1999;725:91–100.
[34] Hage DS, Sengupta A. Studies of protein binding to non-polar solutes by using zonal elution and high-performance affinity chromatography: interactions of cis- and trans-clomiphene with human serum albumin in the presence of β-cyclodextrin. Anal Chem
1998;70:4602–9.
[35] Loun B, Hage DS. Chiral separation mechanisms in proteinbased HPLC columns. I. Thermodynamic studies of R- and S-warfarin binding to immobilized human serum albumin. Anal Chem
1994;66:3814–22.
[36] Yang J, Hage DS. Characterization of the binding and chiral separation of D- and L-tryptophan on a high-performance immobilized
human serum albumin column. J Chromatogr 1993;645:241–50.
[37] Cohen M. Measurement of circulating glycated proteins to monitor intermediateterm changes in glycaemic control. Eur J Clin
Chem Clin Biochem 1992;30:851–9.
[38] Roohk HV, Zaidi AR. A review of glycated albumin as an intermediate glycation index for controlling diabetes. J Diabetes Sci Technol 2008;2:1114–21.
[39] Guerin-Dubourg A, Catan A, Bourdon E, Rondeau P. Structural
modifications of human albumin in diabetes. Diabetes Metab
2012;38:171–8.
[40] Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and
chemically modified derivatives on assays for glycohemoglobin.
Clin Chem 2001;47:153–63.
[41] Zheng CM, Ma WY, Wu CC, Lu KC. Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta
2012;413:1555–61.
[42] Cohen RM, Sacks DB. Comparing multiple measures of glycemia:
how to transition from biomarker to diagnostic test? Clin Chem
2012;58:1615–7.
[43] Lee EY, Lee BW, Kim D, et al. Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2

75
diabetes patients. Acta Diabetol 2011;48:167–72.
[44] Mehrotra R, Kalantar-Zadeh K, Adler S. Assessment of glycemic
control in dialysis patients: glycosylated hemoglobin or glycated
albumin? Clin J Am Soc Nephrol 2011;6:1520–2.
[45] Armbruster DA. Fructosamine: structure, analysis, and clinical
usefulness. Clin Chem 1987;33:2153–63.
[46] Mashiba S, Uchida K, Okuda S, Tomita S. Measurement of glycated albumin by the nitroblue tetrazolium colorimetric method.
Clin Chim Acta 1992;212:3–15.
[47] Kobayashi K, Yoshimoto K, Hirauchi K, Uchida K. A novel colorimetric method for determination of glycated protein based
on 2-keto-glucose release with hydrazine. Biol Pharm Bull
1993;16:195–8.
[48] Baker JR, Zyzak DV, Thorpe SR, Baynes JW. Chemistry of the
fructosamine assay: D-glucosone is the product of oxidation of
Amadori compounds. Clin Chem 1994;40:1950–5.
[49] Yatscoff RW, Tevaarwerk GJ, MacDonald JC. Quantification of
nonenzymically glycated albumin and total serum protein by affinity chromatography. Clin Chem 1984;30:446–9.
[50] Uchida T, Kozuma T, Yasukawa K, Shima K. Glycated albumin
analyzer. Methods Chromatogr 1996;1:33–41.
[51] Poduslo JF, Curran GL. Increased permeability across the blood–
nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci U S A
1992;89:2218–22.
[52] Yasukawa K,Abe F, ShidaN, et al.High-performance affinity chromatography system for the rapid, efficient assay of glycated albumin. J Chromatogr 1992;597:271–5.
[53] Hage DS, Anguizola JA, Bi C, et al. Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments. J Pharm Biomed Anal 2012;69:93–105.
[54] Hage DS. Affinity chromatography: a review of clinical applications. Clin Chem 1999;45:593–615.
[55] Cohen MP, Clements RS. Measuring glycated proteins: clinical
and methodological aspects. Diabetes Technol Ther 1999;1:57–69.
[56] Cohen MP, Hud E. Measurement of plasma glycoalbumin levels
with a monoclonal antibody based ELISA. J Immunol Methods
1989;122:279–83.
[57] Ikeda K, Sakamoto Y, Kawasaki Y, et al. Determination of glycated
albumin by enzyme-linked boronate immunoassay (ELBIA). Clin
Chem 1998;44:256–63.
[58] Paroni R, Ceriotti F, Galanello R, et al. Performance characteristics and clinical utility of an enzymatic method for the
measurement of glycated albumin in plasma. Clin Biochem
2007;40:1398–405.
[59] Kohzuma T, KogaM. Lucica GA-L glycated albumin assay kit.
A new diagnostic test for diabetes mellitus. Mol Diagn Ther
2010;14:49–51.
[60] Kouzuma T, Usami T, YamakoshiM, Takahashi M, Imamura S.
An enzymatic method for the measurement of glycated albumin in
biological samples. Clin Chim Acta 2002;324:61–71.
[61] Wang Y, Dou C, Yuan C, Datta A. Development of an automated
enzymatic assay for the determination of glycated serumprotein in
human serum. Clin Chem 2005;51: 1991–2.
[62] Zhang Q, Tang N, Schepmoes AA, Phillips LS,Smith RD,Metz
TO. Proteomic profiling of nonenzymatically glycated proteins
in human plasma and erythrocyte membranes. J Proteome Res
2008;7:2025–32.
[63] Dingari NC, Horowitz GL, Kang JW, Dasari RR, Barman I. Raman spectroscopy provides a powerful diagnostic tool for accurate
determination of albumin glycation. PLoS One 2012;7:e32406.
[64] Zhernovaya OS, Tuchin VV, Meglinski IV. Monitoring of blood
proteins glycation by refractive index and spectral measurements.
Laser Phys Lett 2008;5:460–4.
[65] Hinton DJS, Ames JM. Analysis of glycated protein by capillary
electrophoresis. Int Congress Ser 2002;1245:471–4.
[66] Pereira MoraisMP, Mackay JD, Bhamra SK, et al. Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. Proteomics 2010;10:48–58.

et al. in

Clinica Chimica Acta 425 (2013)

76

Anguizola

[67] Martin GJ, Rand JS, Hickey SA. Separation of serum glycated proteins by agarose gel electrophoresis and nitroblue tetrazolium staining in diabetic and normal cats. Vet Clin Pathol
2006;35:307–10.
[68] Thornalley PJ. Dicarbonyl intermediates in the Maillard reaction.
Ann N Y Acad Sci 2005;1043:111–7.
[69] Mendez DL, Jensen RA, McElroy LA, Pena JM, Esquerra RM. The
effect of non-enzymatic glycation on the unfolding of human serum albumin. Arch Biochem Biophys 2005;444:92–9.
[70] Fitzpatrick G, Duggan PF. The effect of non-enzymatic glycation
on ligand binding to human serum albumin. Biochem Soc Trans
1987;15:267–8.
[71] Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri
M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 2003;1623:88–97.
[72] Joseph KS, Anguizola J, Jackson AJ, Hage DS. Chromatographic
analysis of acetohexamide binding to glycated human serum albumin. J Chromatogr B 2010;878:2775–81.
[73] Joseph KS, Anguizola J, Hage DS. Binding of tolbutamide
to glycated human serum albumin. J Pharm Biomed Anal
2011;54:426–32.
[74] Joseph KS, Hage DS. The effects of glycation on the binding of
human serum albumin to warfarin and L-tryptophan. J Pharm
Biomed Anal 2010;53:811–8.
[75] Matsuda R, Anguizola J, Joseph KS, Hage DS. High-performance
affinity chromatography and the analysis of drug interactions with
modified proteins: binding of gliclazide with glycated human serum albumin. Anal Bioanal Chem 2011;401: 2811–9.
[76] Garlick RL, Mazer JS. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem
1983;258:6142–6.
[77] Day JF, Thorpe SF, Baynes JW. Nonenzymatically glycosylated albumin. J Biol Chem 1979;254:595–7.
[78] Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin
in vivo: identification of multiple glycosylated sites. J Biol Chem
1986;261:13542–5.
[79] Arif B, Jalaluddin M, Moinuddin A, Ahmad J, Arif Z, Alam K.
Structural and immunological characterization of Amadori-rich
human serum albumin: role in diabetes mellitus. Arch Biochem
Biophys 2012;522:17–25.
[80] Zoellner H, Hou JY, Hochgrebe T, et al. Fluorometric and mass
spectrometric analysis of nonenzymatic glycosylated albumin. BiochemBiophys Res Commun 2001;284:83–9.
[81] Westwood ME, Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified
serum albumins. J Protein Chem 1995;14:359–72.
[82] Barzegar A, Moosavi-Movahedi AA, Sattarahmady N, et al. Spectroscopic studies of the effects of glycation of human serum albumin on L-trp binding. Prot Pep Lett 2007;14:13–8.
[83] Okabe N, Hashizume N. Drug binding properties of glycosylated
human serum albumin as measured by fluorescence and circular
dichroism. Biol Pharm Bull 1994;17:16–21.
[84] Howard MJ, Smales CM. NMR analysis of synthetic human serum albumin α-helix 28 identifies structural distortion upon Amadori modification. J Biol Chem 2005;280:22582–9.
[85] Taneda S, Monnier VM. ELISA of pentosidine, an advanced
glycation endproduct, in biological specimens. Clin Chem
1994;40:1766–73.
[86] Lee C, Yim MB, Chock PB, Yim YS, Kang SO. Oxidation-reduction
properties of methylglyoxal-modified protein in relation to free
radical generation. J Biol Chem 1998;273:25272–8.
[87] Schleicher E, Wieland OH. Specific quantitation by HPLC of protein (lysine) bound glucose in human serum albumin and other
glycosylated proteins. J Clin Chem Clin Biochem 1981;19:81–7.
[88] Ahmed N, Argirov OK, Minhas HS, Cordeiro CAA, Thornalley
PJ. Assay of advanced glycation endproducts (AGEs): surveying
AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate and application to Nε-

carboxymethyl–lysine- and Nε-(1-carboxyethyl)lysine-modified
albumin. Biochem J 2002;364:1–14.
[89] Ahmed N, Thornalley PJ. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization
with 6-aminoquinolyl-Nhydroxysuccinimidyl- carbamate and intrinsic fluorescence. Biochem J 2002;364: 15–24.
[90] Lui X, ScoutenWH. In: Hage DS, editor. Handbook of affinity
chromatography. Boca Raton, FL: CRC Press; 2006 [Chap 8.].
[91] Zhang Q, Monroe ME, Schepmoes AA, et al. Comprehensive identification of glycated peptides and their glycation motifs in plasma
and erythrocytes of control and diabetic subjects. J Proteome Res
2011;10:3076–88.
[92] Frolov A, Hoffman R. Analysis of Amadori peptides enriched
by boronic acid affinity chromatography. Ann N Y Acad Sci
2008;1126:253–6.
[93] Frolov A, Hoffmann R. Identification and relative quantification
of specific glycation sites in human serum albumin. Anal Bioanal
Chem 2010;397:2349–56.
[94] Gadgil HS, Bondarenko PV, Treuheit MJ, Ren D. Screening and
sequencing of glycated proteins by neutral loss scan LC/MS/MS
method. Anal Chem 2007;79: 5991–9.
[95] Kisugi R, Kouzuma T, Yamamoto T, et al. Structural and glycation
site changes of albumin in diabetic patient with very high glycated
albumin. Clin Chim Acta 2007;382:59–64.
[96] Lapolla A, Fedele D, Reitano R, Arico NC. Enzymatic digestion
and mass spectrometry in the studies of advanced glycation end
products/peptides. J Am Soc Mass Spectrom 2004;15:496–509.
[97] Priego-Capote F, Scherl A, Muller M, Waridel P, Lisacek F, Sanchez JC. Glycation isotopic labeling with 13C-reducing sugars for
quantitative analysis of glycated proteins in human plasma. Mol
Cell Proteomics 2010;9:579–97.
[98] Frost L, ChaudhryM, Bell T, CohenfordM. In vitro galactation of
human serum albumin: analysis of the protein’s galactation sites
by mass spectrometry. Anal Biochem 2011;410:248–56.
[99] Ahmed N, Thornalley PJ. Peptide mapping of human serum albumin modified by methylglyoxal in vitro and in vivo. Ann N Y Acad
Sci 2005;1043:260–6.
[100] Ahmed N, Dobler D, DeanM, Thornalley PJ. Peptide mapping
identifies hotspot site of modification in human serum albumin by
methylglyoxal involved in ligand binding and esterase activity. J
Biol Chem 2005;280:5724–32.
[101] Stefanowicz P, Kijewska M, Kluczyk A, Szewczuk Z. Detection of
glycation sites in proteins by high-resolution mass spectrometry
combined with isotopic labeling. Anal Biochem 2010;400:237–43.
[102] Brancia FL, Bereszczak JZ, Lapolla A, et al. Comprehensive analysis of glycated human serumalbumin tryptic peptides by off-line
liquid chromatography followed by MALDI analysis on a time-offlight/curved field reflectron tandem mass spectrometer. J Mass
Spectrom 2006;41:1179–85.
[103] Marotta E, Lapolla A, FedelleD, et al. Accurate mass measurements by Fourier transformmass spectrometry in the study of
advanced glycation end products/peptides. J Mass Spectrom
2003;38:196–205.
[104] Robb DA, Olufemi OS, Williams DA, Midgley JM. Identification
of glycation at the N-terminus of albumin by gas chromatography–mass spectrometry. Biochem J 1986;261:871–8.
[105] Barnaby OS, Wa C, Cerny RL, Clarke W, Hage DS. Quantitative analysis of glycation sites on human serum labeling using
16O/18O labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2010;411:
1102–10.
[106] Barnaby OS, Cerny RL, ClarkeW, Hage DS. Comparison of modification sites formed on human serum albumin at various stages of
glycation. Clin Chim Acta 2011;412: 277–85.
[107] Wa C, Cerny RL, Clarke WA, Hage DS. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin
Chim Acta 2007;385:48–60.
[108] Barnaby OS, Cerny RL, Clarke W, Hage DS. Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-

Review: Glycation

of human serum albumin

labeling and MALDI–TOF MS. Clin Chim Acta 2011;412:1606–15.
[109] Lee BS, Krishnanchettiar S, Lateef SS, Gupta S. Analyses of the
in vitro nonenzymatic glycation of peptides/proteins by matrix-assisted laser desorption/ ionization mass spectrometry. Int J Mass
Spectrom 2007;260:67–74.
[110] Anguizola J, Joseph KS, Barnaby OS, et al. Development of affinity microcolumns for drug–protein binding studies in personalized medicine: interactions of sulfonylurea drugs with in vivo glycated human serum albumin. Anal Chem 2013;85:4453–60.
[111] Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O,
Dawnay A. Mass spectrometric monitoring of albumin in uremia.
Kidney Int 2000;58:2228–34.
[112] Kato H, Hayase F, Shin DB, Oimomi M, Baba S. 3-Deoxyglucosone, an intermediate product of the Maillard reaction. Prog Clin
Biol Res 1989;304:69–84.
[113] Stitt AW, Curtis TM. Advanced glycation and retinal pathology
during diabetes. Pharmacol Rep 2005;57:156–68.
[114] Takeuchi M, Kikuchi S, Sasaki N, et al. Involvement of advanced
glycation endproducts (AGEs) in Alzheimer’s disease. Curr Alzheimer Res 2004;1:39–46.
[115] Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001;56:1–21.
[116] Thornalley PJ. Protein and nucleotide damage by glyoxal and
methylglyoxal in physiological systems — role in ageing and disease. Drug Metabol Drug Interact 2008;23:125–50.
[117] Thornalley PJ. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass
spectrometry. Biochem J 2003;375: 581–92.
[118] Singh R, Barden A, Mori T, Beilin L. Advanced glycation end
products: a review. Diabetologia 2001;44:129–46.
[119] Baraka-Vidot J, Guerin-Dubourg A, Bourdon E, Rondeau P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie 2012;94:1960–7.
[120] Voziyan PA, Khalifah RG, Thibaudeau C, et al. Modification of
proteins in vitro by physiological levels of glucose. J Biol Chem
2003;278:46616–24.
[121] Syrovy I. Glycation of albumin: reaction with glucose, fructose,
galactose, ribose or glyceraldehydes measured using four methods. J Biochem Biophys Methods 1994;28:115–21.
[122] Mereish KA, Rosenberg H, Cobby J. Glucosylated albumin and
its influence on salicylate binding. J Pharm Sci 1982;1:235–8.
[123] Gatti G, Crema F, Attardo-Parrinello G, Fratino P, Aguzzi F,
Perucca E. Serumprotein binding of phenytoin and valproic
acid in insulin-dependent diabetes mellitus. Ther Drug Monit
1987;9:389–91.
[124] McNamara PJ, Blouin RA, Brazzell RK. The protein binding of
phenytoin, propranolol, diazepam and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res
1988;5:261–5.
[125] Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic
drugs in diabetes mellitus. Clin Pharmacol Ther 1984;36:691–5.
[126] Jackson AJ, Anguizola J, Pfaunmiller EL, Hage DS. Use of entrapment and highperformance affinity chromatography to compare the binding of drugs and sitespecific probes with normal and glycated human serum albumin. Anal Bioanal Chem
2013;405:5833–41.
[127] Joseph KS, Hage DS. Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography.
J Chromatogr B 2010;878:1590–8.

76-A
[128] Matsuda R, Anguizola J, Joseph KS, Hage DS. Analysis of drug
interactions with modified proteins by high-performance affinity
chromatography: binding of glibenclamide to normal and glycated
human serum albumin. J Chromatogr A 2012;1265:114–22.
[129] Tsuchiya S, Tamiko S, Sekiguchi S. Nonenzymatic glucosylation
of human serum albumin and its influence on binding capacity of
sulfonylurea drugs. Biochem Pharmacol 1984;33:2967–71.
[130] Koizumi K, Ikeda C, Ito M, et al. Influence of glycosylation on
the drug binding of human serum albumin. Biomed Chromatogr
1998;12:203–10.
[131] Doucet J, Fresel J, Hue G, Moore N. Protein binding of digitoxin,
valproate and phenytoin in sera from diabetics. Eur J Clin Pharmacol 1993;45:577–9.
[132] Bohney JP, Feldhoff RC. Effects of nonenzymatic glycosylation
and fatty acids on tryptophan binding to human serum albumin.
1992;43:1829–34.
[133] Joseph KS, Moser AC, Basiaga S, Schiel JE, Hage DS. Evaluation
of alternatives to warfarin as probes for Sudlow site I of human serum albumin: characterization by high-performance affinity chromatography. J Chromatogr A 2009;1216:3492–500.
[134] Conrad ML, Moser AC, Hage DS. Evaluation of indole-based
probes for highthroughput screening of drug binding to human serum albumin: analysis by high-performance affinity chromatography. J Sep Sci 2009;32:1145–55.
[135] Davis SN. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman
and Gilman’s the pharmacological basis of therapeutics. 11th ed.
New York: McGraw Hill; 2006
[Ch. 60].
[136] Hagstrom-Toft E, Hellstrom L, Moberg E. Lipolytic response
during spontaneous hypoglycaemia in insulin-dependent diabetic
subjects. Horm Metab Res 1998;30: 586–93.
[137] Chase PH, Glasgow AM. Juvenile diabetes mellitus and serum
lipids and lipoprotein levels. Am J Dis Child 1976;130:1113–7.
[138] Bomba-Opon D, Wielgos M, Szymanska M, Bablok L. Effects of
free fatty acids on the course of gestational diabetes mellitus. Neuroendocrinol Lett 2006;27:277–80.
[139] Spector AA. Fatty acid binding to plasma albumin. J Lipid Res
1975;16:165–79.
[140] Noctor TAG,Wainer IW, Hage DS. Allosteric and competitive
displacement of drugs from human serum albumin by octanoic
acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase. J Chromatogr 1992;577:305–15.
[141] Bhattacharya AA, Grüne T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty
acids to human serum albumin. J Mol Biol 2000;303:721–32.
[142] Petitpas I, Grüne T, Bhattacharya AA, Curry S. Crystal structures
of human serum albumin complexed with monounsaturated and
polyunsaturated fatty acids. J Mol Biol 2000;314:955–60.
[143] Richieri GVS, Anel A, Kleinfeld AM. Interactions of longchain fatty acids and albumin: determination of free fatty
acid levels using the fluorescent probe ADIFAB. Biochemistry
1993;32:7574–80.
[144] Basiaga SB, Hage DS. Chromatographic studies of changes in
binding of sulfonylurea drugs to human serumalbumin due to glycation and fatty acids. J Chromatogr B 2010;878:3193–7.
[145] Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 2000;22:313–20.

It is the policy of the University of Nebraska-Lincoln not to discriminate based upon age, race, ethnicity, color, national origin, gender-identity,
sex, pregnancy, disability, sexual orientation, genetic information, veteran’s status, marital status, religion or political affiliation.

